Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model

Autores
del Carmen, Silvina Andrea; Martin Rosique, Rebeca; Saraiva, Tessália; Zurita Turk, Meritxell; Miyoshi, Anderson; Azevedo, Vasco; de Moreno, Maria Alejandra; Langella, Philippe; Bermudez-Humaran, Luis G.; Leblanc, Jean Guy Joseph
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Oral treatment with Lactococcus (L.) lactis strains secreting the anti-inflammatory cytokine IL-10 has previously shown success as a therapy for inflammatory bowel diseases (IBD). Goals: Our aim was to compare the protective effects of IL-10, delivered by recombinant lactoccoci using two novel expression systems, in a murine colitis model mimicking the relapsing nature of IBD. The first system is based on a Stress-Inducible Controlled Expression (SICE) system for the production and delivery of heterologous proteins at mucosal surfaces and the second allows the delivery to the host cells of an il-10 cDNA cassette, harbored in a eukaryotic DNA expression vector (pValac). Study: Colitis was induced in female BALB/c mice by intrarectal injection of 2,4,6-trinitrobenzenesulphonic acid (TNBS). Mice that recovered received one of the bacteria treatments or saline solution orally during 14 days. Colitis was reactivated 25 days after the first TNBS injection with a second TNBS challenge. Three days after colitis reactivation, cytokine profiles and inflammation in colon samples were evaluated. Results: Animals (N=9) receiving L. lactis strains secreting IL-10 using SICE system or delivering pValac:il-10 plasmid showed lower weight loss (p<0.005), lower damage scores (p<0.005) and immune activation in their large intestines compared to inflamed non-treated mice. Conclusions: Our results confirm the protective effect of IL-10 delivered either as a protein or as a cDNA in a colitis model mimicking the relapsing nature of IBD and provides a step further in the ?proof-of-concept? of genetically engineered bacteria as a valid system to deliver therapeutic molecules at mucosal level.
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Martin Rosique, Rebeca. Institut National de la Recherche Agronomique; Francia
Fil: Saraiva, Tessália. Universidade Federal do Minas Gerais; Brasil
Fil: Zurita Turk, Meritxell. Universidade Federal do Minas Gerais; Brasil
Fil: Miyoshi, Anderson. Universidade Federal do Minas Gerais; Brasil
Fil: Azevedo, Vasco. Universidade Federal do Minas Gerais; Brasil
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Langella, Philippe. Institut National de la Recherche Agronomique; Francia
Fil: Bermudez-Humaran, Luis G.. Institut National de la Recherche Agronomique; Francia
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Materia
Lactococcus Lactis
Interleukin-10
Dna Vaccine
Inflammatory Bowel Diseases (Ibd)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/20553
Acceder
id CONICETDig_fb6da94fc2eafacceb345bf86e33167c
oai_identifier_str oai:ri.conicet.gov.ar:11336/20553
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis modeldel Carmen, Silvina AndreaMartin Rosique, RebecaSaraiva, TessáliaZurita Turk, MeritxellMiyoshi, AndersonAzevedo, Vascode Moreno, Maria AlejandraLangella, PhilippeBermudez-Humaran, Luis G.Leblanc, Jean Guy JosephLactococcus LactisInterleukin-10Dna VaccineInflammatory Bowel Diseases (Ibd)https://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Background: Oral treatment with Lactococcus (L.) lactis strains secreting the anti-inflammatory cytokine IL-10 has previously shown success as a therapy for inflammatory bowel diseases (IBD). Goals: Our aim was to compare the protective effects of IL-10, delivered by recombinant lactoccoci using two novel expression systems, in a murine colitis model mimicking the relapsing nature of IBD. The first system is based on a Stress-Inducible Controlled Expression (SICE) system for the production and delivery of heterologous proteins at mucosal surfaces and the second allows the delivery to the host cells of an il-10 cDNA cassette, harbored in a eukaryotic DNA expression vector (pValac). Study: Colitis was induced in female BALB/c mice by intrarectal injection of 2,4,6-trinitrobenzenesulphonic acid (TNBS). Mice that recovered received one of the bacteria treatments or saline solution orally during 14 days. Colitis was reactivated 25 days after the first TNBS injection with a second TNBS challenge. Three days after colitis reactivation, cytokine profiles and inflammation in colon samples were evaluated. Results: Animals (N=9) receiving L. lactis strains secreting IL-10 using SICE system or delivering pValac:il-10 plasmid showed lower weight loss (p<0.005), lower damage scores (p<0.005) and immune activation in their large intestines compared to inflamed non-treated mice. Conclusions: Our results confirm the protective effect of IL-10 delivered either as a protein or as a cDNA in a colitis model mimicking the relapsing nature of IBD and provides a step further in the ?proof-of-concept? of genetically engineered bacteria as a valid system to deliver therapeutic molecules at mucosal level.Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaFil: Martin Rosique, Rebeca. Institut National de la Recherche Agronomique; FranciaFil: Saraiva, Tessália. Universidade Federal do Minas Gerais; BrasilFil: Zurita Turk, Meritxell. Universidade Federal do Minas Gerais; BrasilFil: Miyoshi, Anderson. Universidade Federal do Minas Gerais; BrasilFil: Azevedo, Vasco. Universidade Federal do Minas Gerais; BrasilFil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaFil: Langella, Philippe. Institut National de la Recherche Agronomique; FranciaFil: Bermudez-Humaran, Luis G.. Institut National de la Recherche Agronomique; FranciaFil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaWilliams & Wilkins2014-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/20553del Carmen, Silvina Andrea; Martin Rosique, Rebeca; Saraiva, Tessália; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model; Williams & Wilkins; Journal Of Clinical Gastroenterology; 48; S1; 11-2014; S12-170192-07901539-2031CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1097/MCG.0000000000000235info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jcge/pages/articleviewer.aspx?year=2014&issue=11001&article=00007&type=abstractinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:34Zoai:ri.conicet.gov.ar:11336/20553instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:34.67CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
title Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
spellingShingle Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
del Carmen, Silvina Andrea
Lactococcus Lactis
Interleukin-10
Dna Vaccine
Inflammatory Bowel Diseases (Ibd)
title_short Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
title_full Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
title_fullStr Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
title_full_unstemmed Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
title_sort Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model
dc.creator.none.fl_str_mv del Carmen, Silvina Andrea
Martin Rosique, Rebeca
Saraiva, Tessália
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
Langella, Philippe
Bermudez-Humaran, Luis G.
Leblanc, Jean Guy Joseph
author del Carmen, Silvina Andrea
author_facet del Carmen, Silvina Andrea
Martin Rosique, Rebeca
Saraiva, Tessália
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
Langella, Philippe
Bermudez-Humaran, Luis G.
Leblanc, Jean Guy Joseph
author_role author
author2 Martin Rosique, Rebeca
Saraiva, Tessália
Zurita Turk, Meritxell
Miyoshi, Anderson
Azevedo, Vasco
de Moreno, Maria Alejandra
Langella, Philippe
Bermudez-Humaran, Luis G.
Leblanc, Jean Guy Joseph
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Lactococcus Lactis
Interleukin-10
Dna Vaccine
Inflammatory Bowel Diseases (Ibd)
topic Lactococcus Lactis
Interleukin-10
Dna Vaccine
Inflammatory Bowel Diseases (Ibd)
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.11
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Background: Oral treatment with Lactococcus (L.) lactis strains secreting the anti-inflammatory cytokine IL-10 has previously shown success as a therapy for inflammatory bowel diseases (IBD). Goals: Our aim was to compare the protective effects of IL-10, delivered by recombinant lactoccoci using two novel expression systems, in a murine colitis model mimicking the relapsing nature of IBD. The first system is based on a Stress-Inducible Controlled Expression (SICE) system for the production and delivery of heterologous proteins at mucosal surfaces and the second allows the delivery to the host cells of an il-10 cDNA cassette, harbored in a eukaryotic DNA expression vector (pValac). Study: Colitis was induced in female BALB/c mice by intrarectal injection of 2,4,6-trinitrobenzenesulphonic acid (TNBS). Mice that recovered received one of the bacteria treatments or saline solution orally during 14 days. Colitis was reactivated 25 days after the first TNBS injection with a second TNBS challenge. Three days after colitis reactivation, cytokine profiles and inflammation in colon samples were evaluated. Results: Animals (N=9) receiving L. lactis strains secreting IL-10 using SICE system or delivering pValac:il-10 plasmid showed lower weight loss (p<0.005), lower damage scores (p<0.005) and immune activation in their large intestines compared to inflamed non-treated mice. Conclusions: Our results confirm the protective effect of IL-10 delivered either as a protein or as a cDNA in a colitis model mimicking the relapsing nature of IBD and provides a step further in the ?proof-of-concept? of genetically engineered bacteria as a valid system to deliver therapeutic molecules at mucosal level.
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Martin Rosique, Rebeca. Institut National de la Recherche Agronomique; Francia
Fil: Saraiva, Tessália. Universidade Federal do Minas Gerais; Brasil
Fil: Zurita Turk, Meritxell. Universidade Federal do Minas Gerais; Brasil
Fil: Miyoshi, Anderson. Universidade Federal do Minas Gerais; Brasil
Fil: Azevedo, Vasco. Universidade Federal do Minas Gerais; Brasil
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Langella, Philippe. Institut National de la Recherche Agronomique; Francia
Fil: Bermudez-Humaran, Luis G.. Institut National de la Recherche Agronomique; Francia
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
description Background: Oral treatment with Lactococcus (L.) lactis strains secreting the anti-inflammatory cytokine IL-10 has previously shown success as a therapy for inflammatory bowel diseases (IBD). Goals: Our aim was to compare the protective effects of IL-10, delivered by recombinant lactoccoci using two novel expression systems, in a murine colitis model mimicking the relapsing nature of IBD. The first system is based on a Stress-Inducible Controlled Expression (SICE) system for the production and delivery of heterologous proteins at mucosal surfaces and the second allows the delivery to the host cells of an il-10 cDNA cassette, harbored in a eukaryotic DNA expression vector (pValac). Study: Colitis was induced in female BALB/c mice by intrarectal injection of 2,4,6-trinitrobenzenesulphonic acid (TNBS). Mice that recovered received one of the bacteria treatments or saline solution orally during 14 days. Colitis was reactivated 25 days after the first TNBS injection with a second TNBS challenge. Three days after colitis reactivation, cytokine profiles and inflammation in colon samples were evaluated. Results: Animals (N=9) receiving L. lactis strains secreting IL-10 using SICE system or delivering pValac:il-10 plasmid showed lower weight loss (p<0.005), lower damage scores (p<0.005) and immune activation in their large intestines compared to inflamed non-treated mice. Conclusions: Our results confirm the protective effect of IL-10 delivered either as a protein or as a cDNA in a colitis model mimicking the relapsing nature of IBD and provides a step further in the ?proof-of-concept? of genetically engineered bacteria as a valid system to deliver therapeutic molecules at mucosal level.
publishDate 2014
dc.date.none.fl_str_mv 2014-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/20553
del Carmen, Silvina Andrea; Martin Rosique, Rebeca; Saraiva, Tessália; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model; Williams & Wilkins; Journal Of Clinical Gastroenterology; 48; S1; 11-2014; S12-17
0192-0790
1539-2031
CONICET Digital
CONICET
url http://hdl.handle.net/11336/20553
identifier_str_mv del Carmen, Silvina Andrea; Martin Rosique, Rebeca; Saraiva, Tessália; Zurita Turk, Meritxell; Miyoshi, Anderson; et al.; Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model; Williams & Wilkins; Journal Of Clinical Gastroenterology; 48; S1; 11-2014; S12-17
0192-0790
1539-2031
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1097/MCG.0000000000000235
info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jcge/pages/articleviewer.aspx?year=2014&issue=11001&article=00007&type=abstract
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Williams & Wilkins
publisher.none.fl_str_mv Williams & Wilkins
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269469841293312
score 13.13397

Publicaciones similares